Type something to search...

CRISPR in 2026: Why We Are Finally Curing the 'Incurable'

Exienent(Updated )03 Mins read
CRISPR in 2026: Why We Are Finally Curing the 'Incurable'

CRISPR gene editing has crossed from the lab into approved medicine: Casgevy, the first CRISPR-based therapy, has been approved in the U.S. since December 2023 for sickle cell disease and since January 2024 for beta thalassemia. Newer in-body treatments for high cholesterol and rare liver diseases are in trials with promising early data. The open problems are a $2.2 million price tag, safety signals in some trials, and the ethics of editing embryos.

Which diseases can CRISPR treat today?

Only two have an approved CRISPR therapy in the U.S. so far: sickle cell disease and transfusion-dependent beta thalassemia. The FDA approved Casgevy for sickle cell disease in patients 12 and older on December 8, 2023, calling it the first FDA-approved treatment to use CRISPR/Cas9 genome editing (FDA). Approval for beta thalassemia followed on January 16, 2024 (BioPharma Dive).

Casgevy is an ex vivo treatment, not a simple injection. Doctors collect the patient's own blood stem cells, edit them in a lab and infuse them back as a single dose, after high-dose chemotherapy to clear the bone marrow, according to the FDA. That makes it demanding for patients and hospitals alike.

Did CRISPR cure inherited blindness?

No. Editas Medicine's EDIT-101, which injected CRISPR directly into the eye to treat a form of Leber congenital amaurosis, was well tolerated, but only 3 of 14 treated patients met the threshold for meaningful vision improvement. Editas paused enrollment in November 2022 and looked for a partner instead (GEN). It is a reminder that working in a trial is not the same as working for most patients.

Can gene editing lower cholesterol for life?

It is being tested, and early results are encouraging but not proven. Lilly's VERVE-102, a base editor that switches off the PCSK9 gene in the liver with a single infusion, cut LDL cholesterol by up to 62% at the highest dose in an interim Phase 1b analysis of 35 people, with effects lasting up to 18 months and no treatment-related serious adverse events reported (Clinical Trials Arena). Phase 2 is planned to start by the end of 2026.

Dose (mg/kg)Mean LDL-C reduction
0.4544%
0.851%
1.062%

These are small, open-label, company-reported numbers. Whether a one-time edit actually reduces heart attacks remains to be shown.

Are in-body CRISPR treatments safe?

Mostly so far, but not always. In-body (in vivo) treatments rely on lipid nanoparticles, tiny fat bubbles that carry the editing machinery to the liver. In October 2025 the FDA placed clinical holds on Intellia's Phase 3 trials of nex-z, a CRISPR therapy for transthyretin amyloidosis, after a patient developed severe liver toxicity; the patient died in November 2025 (CGTLive). Intellia reported that fewer than 1% of dosed MAGNITUDE patients had had that grade of liver enzyme elevation.

What comes after CRISPR-Cas9?

Base editing and prime editing, which change DNA letters without cutting both strands of the double helix. The most striking example so far is a baby known as KJ, treated in 2025 at Children's Hospital of Philadelphia for a rare liver disorder, CPS1 deficiency. The team designed and made a base editor for his specific mutation within six months and delivered it to his liver in lipid nanoparticles. After three doses he had no serious side effects and could tolerate more protein, though doctors stress he is a single patient who will need lifelong monitoring (CHOP).

How much do CRISPR therapies cost?

Casgevy's U.S. list price is $2.2 million for both sickle cell disease and beta thalassemia (BioPharma Dive). The organizers of the Third International Summit on Human Genome Editing called the "extremely high costs" of current somatic gene therapies "unsustainable" and urged a global commitment to affordable access (Royal Society).

Is it ethical to edit embryos?

The scientific consensus is that it is not acceptable yet. Approved and trial therapies are all somatic: they change the patient's own cells, and the edits aren't passed to children. Germline (heritable) editing changes embryos or reproductive cells so the edits are inherited. The same 2023 summit statement said "heritable human genome editing remains unacceptable at this time," because governance frameworks and safety standards are not in place (Royal Society).

CRISPR medicine is real, but in 2026 it is still a handful of expensive, demanding therapies plus a promising pipeline, not a cure for everything.

Related Post

The End of the Waitlist? 3D Bioprinting Organs in 2026
Health

The End of the Waitlist? 3D Bioprinting Organs in 2026

3D bioprinting can make an ear implant from a patient's own cells and tissue for drug tests, but printing blood vessels keeps transplant organs years away.

24 Jul, 2026·03 Mins read
3D Food Printers at Home: Is This the Future of Cooking?
Lifestyle

3D Food Printers at Home: Is This the Future of Cooking?

Home 3D food printers extrude purees and doughs into precise shapes but don't cook them, so they suit pastry and presentation, not quick weeknight meals.

03 Jul, 2026·03 Mins read
Ditching 2D Photos for 3D Gaussian Splatting: Is This the Future of Memories?
Technology

Ditching 2D Photos for 3D Gaussian Splatting: Is This the Future of Memories?

Phone apps like Scaniverse now build photorealistic 3D Gaussian splats on the device. Great for rooms and static scenes, but moving subjects and sharing lag photos.

17 Aug, 2026·03 Mins read